Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
North Shore University Hospital
mi
from
Manhasset, NY
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
North Shore University Hospital
mi
from
Manhasset, NY
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
University of Rochester Cancer Center
mi
from
Rochester, NY
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
University of Rochester Cancer Center
mi
from
Rochester, NY
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
State University of New York Health Sciences Center - Stony Brook
mi
from
Stony Brook, NY
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
State University of New York Health Sciences Center - Stony Brook
mi
from
Stony Brook, NY
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
Lineberger Comprehensive Cancer Center, UNC
mi
from
Chapel Hill, NC
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
Lineberger Comprehensive Cancer Center, UNC
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
Duke Comprehensive Cancer Center
mi
from
Durham, NC
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
Duke Comprehensive Cancer Center
mi
from
Durham, NC
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
Brookview Research, Inc.
mi
from
Winston-Salem, NC
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
Brookview Research, Inc.
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
Comprehensive Cancer Center of Wake Forest University Baptist Medical Center
mi
from
Winston-Salem, NC
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
Comprehensive Cancer Center of Wake Forest University Baptist Medical Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
Barrett Cancer Center, The University Hospital
mi
from
Cincinnati, OH
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
Barrett Cancer Center, The University Hospital
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
Ireland Cancer Center
mi
from
Cleveland, OH
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
Ireland Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
Cleveland Clinic Cancer Center
mi
from
Cleveland, OH
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
Cleveland Clinic Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
Arthur G. James Cancer Hospital - Ohio State University
mi
from
Columbus, OH
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
Arthur G. James Cancer Hospital - Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
University of Oklahoma College of Medicine
mi
from
Oklahoma City, OK
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
University of Oklahoma College of Medicine
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
CCOP - St. Francis Hospital/Natalie Warren Bryant Cancer Center
mi
from
Tulsa, OK
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
CCOP - St. Francis Hospital/Natalie Warren Bryant Cancer Center
mi
from
Tulsa, OK
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
CCOP - Columbia River Program
mi
from
Portland, OR
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
CCOP - Columbia River Program
mi
from
Portland, OR
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
Abington Memorial Hospital
mi
from
Abington, PA
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
Abington Memorial Hospital
mi
from
Abington, PA
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
The Milton S. Hershey Medical Center
mi
from
Hershey, PA
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
The Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
University of Pennsylvania Cancer Center
mi
from
Philadelphia, PA
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
University of Pennsylvania Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
mi
from
Philadelphia, PA
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
Pennsylvania Hospital
mi
from
Philadelphia, PA
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
Pennsylvania Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
Medical University of South Carolina
mi
from
Charleston, SC
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
CCOP - Upstate Carolina
mi
from
Spartanburg, SC
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
CCOP - Upstate Carolina
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
CCOP - Baptist Cancer Institute
mi
from
Memphis, TN
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
CCOP - Baptist Cancer Institute
mi
from
Memphis, TN
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
Simmons Cancer Center - Dallas
mi
from
Dallas, TX
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
Simmons Cancer Center - Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
Cancer Center, University of Virginia HSC
mi
from
Charlottesville, VA
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
Cancer Center, University of Virginia HSC
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
University of Washington Medical Center
mi
from
Seattle, WA
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
Tacoma General Hospital
mi
from
Tacoma, WA
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
Tacoma General Hospital
mi
from
Tacoma, WA
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
NCIC-Clinical Trials Group
mi
from
Kingston,
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
NCIC-Clinical Trials Group
mi
from
Kingston,
Click here to add this to my saved trials
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated:  4/11/2018
University of Alabama Comprehensive Cancer Center
mi
from
Birmingham, AL
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated: 4/11/2018
University of Alabama Comprehensive Cancer Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated:  4/11/2018
CCOP - Greater Phoenix
mi
from
Phoenix, AZ
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated: 4/11/2018
CCOP - Greater Phoenix
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated:  4/11/2018
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated: 4/11/2018
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated:  4/11/2018
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated: 4/11/2018
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated:  4/11/2018
Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated: 4/11/2018
Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Click here to add this to my saved trials
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated:  4/11/2018
Women's Cancer Center
mi
from
Palo Alto, CA
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated: 4/11/2018
Women's Cancer Center
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated:  4/11/2018
University of Colorado Cancer Center
mi
from
Denver, CO
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated: 4/11/2018
University of Colorado Cancer Center
mi
from
Denver, CO
Click here to add this to my saved trials
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated:  4/11/2018
Vincent T. Lombardi Cancer Research Center, Georgetown University
mi
from
Washington,
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated: 4/11/2018
Vincent T. Lombardi Cancer Research Center, Georgetown University
mi
from
Washington,
Click here to add this to my saved trials
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated:  4/11/2018
Walter Reed Army Medical Center
mi
from
Washington,
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated: 4/11/2018
Walter Reed Army Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated:  4/11/2018
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated: 4/11/2018
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated:  4/11/2018
Emory University Hospital - Atlanta
mi
from
Atlanta, GA
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated: 4/11/2018
Emory University Hospital - Atlanta
mi
from
Atlanta, GA
Click here to add this to my saved trials
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated:  4/11/2018
MBCCOP - Hawaii
mi
from
Honolulu, HI
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated: 4/11/2018
MBCCOP - Hawaii
mi
from
Honolulu, HI
Click here to add this to my saved trials
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated:  4/11/2018
MBCCOP - University of Illinois at Chicago
mi
from
Chicago, IL
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated: 4/11/2018
MBCCOP - University of Illinois at Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated:  4/11/2018
Rush-Presbyterian-St. Luke's Medical Center
mi
from
Chicago, IL
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated: 4/11/2018
Rush-Presbyterian-St. Luke's Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated:  4/11/2018
University of Chicago Cancer Research Center
mi
from
Chicago, IL
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated: 4/11/2018
University of Chicago Cancer Research Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated:  4/11/2018
CCOP - Central Illinois
mi
from
Decatur, IL
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated: 4/11/2018
CCOP - Central Illinois
mi
from
Decatur, IL
Click here to add this to my saved trials
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated:  4/11/2018
CCOP - Evanston
mi
from
Evanston, IL
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated: 4/11/2018
CCOP - Evanston
mi
from
Evanston, IL
Click here to add this to my saved trials
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated:  4/11/2018
Indiana University Cancer Center
mi
from
Indianapolis, IN
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated: 4/11/2018
Indiana University Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated:  4/11/2018
CCOP - Iowa Oncology Research Association
mi
from
Des Moines, IA
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated: 4/11/2018
CCOP - Iowa Oncology Research Association
mi
from
Des Moines, IA
Click here to add this to my saved trials
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated:  4/11/2018
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated: 4/11/2018
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Click here to add this to my saved trials